comparemela.com

Latest Breaking News On - Hyloris pharmaceuticals sa stock exchange - Page 1 : comparemela.com

Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

Regulated Information - Liège, Belgium – 08 June 2023 – 6 PM CET – Hyloris Pharmaceuticals SA , a specialty biopharma company committed to addressing unmet medical. | June 8, 2023

Waals gewestWalloon regionStijn van rompaySven watthyWilly borsusJean luc vandebroekHyloris pharmaceuticals sa euronext brusselsHyloris pharmaceuticalsInvestor relations communicationsTerritorial developmentEuronext brusselsForeign tradeVan rompayChief executive officerInnovation willy borsusLuc vandebroek

Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA

Additional extractable & leachable data generated by an accredited lab facility located in North AmericaResults analyzed and evaluated by toxicological expertsPotential regulatory approval for. | April 18, 2023

United statesStijn van rompaySven watthyJean luc vandebroekHyloris pharmaceuticalsInvestor relations communicationsHikma pharmaceuticalsHyloris pharmaceuticals sa euronext brusselsFood drug administrationEuronext brusselsDrug administrationComplete response letterVan rompayChief executive officerLuc vandebroekInvestor relations

Hyloris Successfully Raises EUR 15 0 Million in an Equity Offering by Means of A Private Placement Via an Accelerated Bookbuild Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS. | April 1, 2022

United statesUnited kingdomSouth africaStijn van rompayHyloris pharmaceuticalsEuropean parliamentGossler coEuropean union withdrawal agreementSwiss federal act on financial services finanzdienstleistungsgesetzStifel nicolaus europe limitedHyloris pharmaceuticals sa euronext brusselsEuropean union withdrawalEu pressCompany or hylorisEuronext brusselsVan rompay

UPDATE – Hyloris Launches Equity Offering by Means of a Private Placement Via an Accelerated Bookbuild Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS. | March 31, 2022

United statesUnited kingdomSouth africaBelgian companiesEuropean parliamentGossler coHyloris pharmaceuticalsEuropean union withdrawal agreementSwiss federal act on financial services finanzdienstleistungsgesetzStifel nicolaus europe limitedBelgian code of companiesHyloris pharmaceuticals sa euronext brusselsEuropean union withdrawalCompany the committeeAssociation codeCompany or hyloris

Hyloris reports results for the full year 2021

Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million Significant expansion of commercial footprint of Maxigesic® IV . | March 16, 2022

United kingdomNew zealandSouth koreaThomas jacobsenVaneltix pharmaVulvovaginal candidiasisOlivier declercqAbid irshadJean luc vandebroekStijn van rompayChris buyseDelveinsight market researchAlter pharma groupDepartment of radiologyUniversity of south carolina college medicineHyloris pharmaceuticals

vimarsana © 2020. All Rights Reserved.